ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Connecticut » Pulmonary Disease

Top Pulmonary Disease Prescribers in Connecticut

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
POOJA BELLIGUND MBBS

Pulmonary Disease

1,536

$289K

215
115 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

60%
prescriptions for brand name drugs

Avg: 64%

$188
Average prescription price

Avg: $170

KATHLEEN CHAISSON M.D.

Pulmonary Disease

1,476

$226K

177
137 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 64%

$153
Average prescription price

Avg: $170

JOHN CHRONAKOS M.D.

Pulmonary Disease

1,406

$410K

335
285 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 64%

$291
Average prescription price

Avg: $170

RICHARD ZUWALLACK MD

Pulmonary Disease

1,405

$224K

139
101 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 64%

$159
Average prescription price

Avg: $170

ANTON CHINNIAH M.D.

Pulmonary Disease

1,389

$113K

82
58 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 64%

$81
Average prescription price

Avg: $170

EDWARD SALERNO MD

Pulmonary Disease

1,318

$434K

237
176 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 64%

$329
Average prescription price

Avg: $170

ROBERT BUNDY M.D.

Pulmonary Disease

1,294

$334K

214
163 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 64%

$258
Average prescription price

Avg: $170

BIMALIN LAHIRI MD

Pulmonary Disease

1,261

$854K

160
144 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 64%

$677
Average prescription price

Avg: $170

RAYMOND FOLEY D.O.

Pulmonary Disease

1,258

$1.16M

158
106 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 64%

$923
Average prescription price

Avg: $170

OLIMPIA RADU MD

Pulmonary Disease

1,194

$250K

176
126 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 64%

$209
Average prescription price

Avg: $170

STUART MCCALLEY M.D.

Pulmonary Disease

1,192

$247K

176
167 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 64%

$207
Average prescription price

Avg: $170

DANIEL GERARDI MD

Pulmonary Disease

1,169

$322K

172
142 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 64%

$276
Average prescription price

Avg: $170

MARI ADACHI MD

Pulmonary Disease

1,142

$209K

201
124 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 64%

$183
Average prescription price

Avg: $170

LAURENCE NAIR MD

Pulmonary Disease

1,131

$188K

141
113 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 64%

$166
Average prescription price

Avg: $170

SETU VORA MD

Pulmonary Disease

1,097

$210K

215
171 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 64%

$192
Average prescription price

Avg: $170

JOHN MCARDLE MD

Pulmonary Disease

1,067

$359K

210
169 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 64%

$337
Average prescription price

Avg: $170

TAPAS BANDYOPADHYAY MD

Pulmonary Disease

1,032

$278K

215
170 are 65+

9%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 64%

$269
Average prescription price

Avg: $170

A MARINO M.D.

Pulmonary Disease

1,027

$228K

148
140 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

79%
prescriptions for brand name drugs

Avg: 64%

$222
Average prescription price

Avg: $170

ASHER QURESHI MD

Pulmonary Disease

1,003

$242K

161
92 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

60%
prescriptions for brand name drugs

Avg: 64%

$241
Average prescription price

Avg: $170

SYED ANEES M.D.

Pulmonary Disease

965

$172K

197
168 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

73%
prescriptions for brand name drugs

Avg: 64%

$178
Average prescription price

Avg: $170

PAUL SACHS M.D.

Pulmonary Disease

949

$224K

132
116 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

86%
prescriptions for brand name drugs

Avg: 64%

$236
Average prescription price

Avg: $170

MICHAEL MCNAMEE MD

Pulmonary Disease

918

$158K

96
62 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

80%
prescriptions for brand name drugs

Avg: 64%

$172
Average prescription price

Avg: $170

PHILIP GREENSPAN MD

Pulmonary Disease

865

$144K

172
138 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

82%
prescriptions for brand name drugs

Avg: 64%

$167
Average prescription price

Avg: $170

PETER PACE M.D.

Pulmonary Disease

858

$161K

119
100 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 64%

$187
Average prescription price

Avg: $170

CHRISTINE WOLLSCHLAGER MD

Pulmonary Disease

839

$169K

96
88 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

84%
prescriptions for brand name drugs

Avg: 64%

$201
Average prescription price

Avg: $170

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank